3-BromocytisineCAS# 207390-14-5 |
- BAM7
Catalog No.:BCC1397
CAS No.:331244-89-4
- Bendamustine HCl
Catalog No.:BCC1153
CAS No.:3543-75-7
- Capsaicin
Catalog No.:BCN1016
CAS No.:404-86-4
- Betulinic acid
Catalog No.:BCN5524
CAS No.:472-15-1
- Brassinolide
Catalog No.:BCC1438
CAS No.:72962-43-7
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 207390-14-5 | SDF | Download SDF |
| PubChem ID | 15519735 | Appearance | Powder |
| Formula | C11H13BrN2O | M.Wt | 269.14 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in water and to 100 mM in DMSO | ||
| Chemical Name | (1R,9S)-5-bromo-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one | ||
| SMILES | C1C2CNCC1C3=CC=C(C(=O)N3C2)Br | ||
| Standard InChIKey | DWDCLEHDNICBMI-JGVFFNPUSA-N | ||
| Standard InChI | InChI=1S/C11H13BrN2O/c12-9-1-2-10-8-3-7(4-13-5-8)6-14(10)11(9)15/h1-2,7-8,13H,3-6H2/t7-,8+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent agonist of α4β4, α4β2 and α7 nACh receptors (IC50 values are 0.28, 0.30 and 31.6 nM respectively). Displays different effects on high (HS) and low (LS) ACh sensitivity α4β2 nAChRs (EC50 values are 0.008 and 0.05 μM respectively). |
3-Bromocytisine Dilution Calculator
3-Bromocytisine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.7155 mL | 18.5777 mL | 37.1554 mL | 74.3108 mL | 92.8885 mL |
| 5 mM | 0.7431 mL | 3.7155 mL | 7.4311 mL | 14.8622 mL | 18.5777 mL |
| 10 mM | 0.3716 mL | 1.8578 mL | 3.7155 mL | 7.4311 mL | 9.2888 mL |
| 50 mM | 0.0743 mL | 0.3716 mL | 0.7431 mL | 1.4862 mL | 1.8578 mL |
| 100 mM | 0.0372 mL | 0.1858 mL | 0.3716 mL | 0.7431 mL | 0.9289 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Dihydrosinapylalcohol
Catalog No.:BCN6542
CAS No.:20736-25-8
- Saikosaponin A
Catalog No.:BCN1086
CAS No.:20736-09-8
- Saikosaponin C
Catalog No.:BCN1087
CAS No.:20736-08-7
- 1,8-Bis(dimethylamino)naphtalene
Catalog No.:BCC8429
CAS No.:20734-58-1
- Methyl sinapate
Catalog No.:BCN4675
CAS No.:20733-94-2
- TB 21007
Catalog No.:BCC7510
CAS No.:207306-50-1
- Fustin
Catalog No.:BCN4904
CAS No.:20725-03-5
- Norlichexanthone
Catalog No.:BCN4903
CAS No.:20716-98-7
- Neosperidin dihydrochalcone
Catalog No.:BCN5016
CAS No.:20702-77-6
- BD 1063 dihydrochloride
Catalog No.:BCC6832
CAS No.:206996-13-6
- Methysticin
Catalog No.:BCN2306
CAS No.:20697-20-5
- Tariquidar
Catalog No.:BCC3625
CAS No.:206873-63-4
- MR 16728 hydrochloride
Catalog No.:BCC6684
CAS No.:207403-36-9
- Arteannuin L
Catalog No.:BCN4905
CAS No.:207446-89-7
- Arteannuin M
Catalog No.:BCN4906
CAS No.:207446-90-0
- Arteannuin N
Catalog No.:BCN4907
CAS No.:207446-92-2
- N-MPPP Hydrochloride
Catalog No.:BCC5672
CAS No.:207452-97-9
- L-693,403 maleate
Catalog No.:BCC5657
CAS No.:207455-21-8
- BTCP maleate
Catalog No.:BCC6753
CAS No.:207455-25-2
- (±)-1-(1,2-Diphenylethyl)piperidine maleate
Catalog No.:BCC6619
CAS No.:207461-99-2
- Pirlindole mesylate
Catalog No.:BCC6764
CAS No.:207572-66-5
- iso-PPADS tetrasodium salt
Catalog No.:BCC6749
CAS No.:207572-67-6
- SB 203186 hydrochloride
Catalog No.:BCC5673
CAS No.:207572-69-8
- H-Phe(4-NO2)-OH.H2O
Catalog No.:BCC3273
CAS No.:207591-86-4
Increase in locomotor activity after acute administration of the nicotinic receptor agonist 3-bromocytisine in rats.[Pubmed:20184877]
Eur J Pharmacol. 2010 May 25;634(1-3):89-94.
Nicotinic acetylcholine receptors influence striatal dopaminergic activity and its outcome on motor behavior. For these reasons, nicotinic receptors have been considered as therapeutically relevant targets for Parkinson's disease, in which a dramatic loss of dopamine affects motor functions. The aim of the present work was to compare the effects on locomotor activity induced by the nicotinic agonist cytisine and two brominated derivatives, 5- and 3-Bromocytisine (5-BrCy and 3-BrCy) using nicotine for comparison. After acute systemic administration of the agonists only 3-BrCy induced an increase in locomotor activity. To study the mechanism of action involved in this increase we co-administered 3-BrCy with the nicotinic antagonist mecamylamine and also examined 3-BrCy's effects in rats pre-treated with the long acting nicotinic antagonist chlorisondamine, administered directly in the dorsal and ventral striatum. We studied the role of the dopaminergic system by co-administration of the D2 dopamine receptor antagonist, haloperidol. The results indicate that the increase in motor activity elicited by 3-BrCy was mediated by nicotinic receptors in the dorsal and ventral striatum and depends on the interaction of nicotinic receptors with the dopaminergic system. We conclude that 3-BrCy might be a new tool to study the modulation of the dopaminergic system by nicotinic receptors and their behavioral implications.
alpha4beta2 nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine.[Pubmed:16720757]
Mol Pharmacol. 2006 Aug;70(2):755-68.
alpha4 and beta2 nicotinic acetylcholine receptor (nAChR) subunits expressed heterologously assemble into receptors with high (HS) and low (LS) sensitivity to acetylcholine (ACh); their relative proportions depend on the alpha4to beta2 ratio. In this study, injection of oocytes with 1:10 alpha4/beta2 subunit cDNA ratios favored expression of HS alpha4beta2 nAChRs, as evidenced by monophasic ACh concentration-response curves, whereas injections with 10:1 cDNA ratios favored expression of LS alpha4beta2 receptors. The stoichiometry was inferred from the shifts in the ACh EC(50) values caused by Leu to Thr mutations at position 9' of the second transmembrane domain of alpha4 and beta2. The 1:10 injection ratio produced the (alpha4)(2)(beta2)(3) stoichiometry, whereas 10:1 injections produced the (alpha4)(3)(beta2)(2) stoichiometry. The agonists epibatidine, 3-[2(S)-azetidinylmethoxy]pyridine (A-85380), 5-ethoxy-metanicotine (TC-2559), cytisine, and 3-Br-cytisine and the antagonists dihydro-beta-erythroidine and d-tubocurarine were more potent at HS receptors. TC-2559 was more efficacious than ACh at HS receptors but was a partial agonist at LS receptors. Epibatidine was more efficacious than ACh at LS receptors and a partial agonist at HS receptors. Cytisine and 5-halogenated cytisines had moderate efficacy at LS receptors but had almost no efficacy at HS receptors. By exploiting the differential effects of ACh, TC-2559 and 5-I-cytisine we evaluated the effects of long-term exposure to nicotine on HS and LS receptors expressed in Xenopus laevis oocytes after cDNA injections or microtransplantation of alpha4beta2 receptors assembled in human embryonic kidney 293 cells. We conclude that nicotine up-regulates HS alpha4beta2 receptors, probably by influencing the assembly of receptors rather than by altering the functional state of LS alpha4beta2 nAChRs.
Activity of cytisine and its brominated isosteres on recombinant human alpha7, alpha4beta2 and alpha4beta4 nicotinic acetylcholine receptors.[Pubmed:11553677]
J Neurochem. 2001 Sep;78(5):1029-43.
Effects of cytisine (cy), 3-Bromocytisine (3-Br-cy), 5-bromocytisine (5-Br-cy) and 3,5-dibromocytisine (3,5-diBr-cy) on human (h) alpha7-, alpha4beta2- and alpha4beta4 nicotinic acetylcholine (nACh) receptors, expressed in Xenopus oocytes and cell lines, have been investigated. Cy and its bromo-isosteres fully inhibited binding of both [alpha-(125)I]bungarotoxin ([alpha-(125)I]BgTx) to halpha7- and [(3)H]cy to halpha4beta2- or halpha4beta4-nACh receptors. 3-Br-cy was the most potent inhibitor of both [alpha-(125)I]BgTx and [(3)H]cy binding. Cy was less potent than 3-Br-cy, but 5-Br-cy and 3,5-diBr-cy were the least potent inhibitors. Cy and 3-Br-cy were potent full agonists at halpha7-nACh receptors but behaved as partial agonists at halpha4beta2- and halpha4beta4-nACh receptors. 5-Br-cy and 3,5-diBr-cy had low potency and were partial agonists at halpha7- and halpha4beta4-nACh receptors, but they elicited no responses on halpha4beta2-nACh receptors. Cy and 3-Br-cy produced dual dose-response curves (DRC) at both halpha4beta2- and halpha4beta4-nACh receptors, but ACh produced dual DRC only at halpha4beta2-nACh receptors. Low concentrations of cy, 3-Br-cy and 5-Br-cy enhanced ACh responses of oocytes expressing halpha4beta2-nACh receptors, but at high concentrations they inhibited the responses. In contrast, 3,5-diBr-cy only inhibited, in a competitive manner, ACh responses of halpha4beta2-nACh receptors. It is concluded that bromination of the pyridone ring of cy produces marked changes in effects of cy that are manifest as nACh receptor subtype-specific differences in binding affinities and in functional potencies and efficacies.
